Treatment with biologic therapies and the risk of cancer in patients with IBD (original) (raw)

• Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182–205
  Article CAS Google Scholar
• MacDonald TT and Monteleone G (2005) Immunity, inflammation, and allergy in the gut. Science 307: 1920–1925
  Article CAS Google Scholar
• Knight DM et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443–1453
  Article CAS Google Scholar
• Hanauer SB (2003). Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131–137
  Article Google Scholar
• Hanauer SB (2005) Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. [Editorial] Nat Clin Pract Gastroenterol Hepatol 2: 493
  Article Google Scholar
• Fiocchi C (2004) Closing fistulas in Crohn's disease—should the accent be on maintenance or safety? N Engl J Med 350: 934–936
  Article CAS Google Scholar
• Munkholm P et al. (1993) Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105: 1716–1723
  Article CAS Google Scholar
• van Dullemen HM et al. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129–135
  Article CAS Google Scholar
• Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029–1035
  Article CAS Google Scholar
• Rutgeerts P et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117: 761–769
  Article CAS Google Scholar
• Present DH et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398–1405
  Article CAS Google Scholar
• Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549
  Article CAS Google Scholar
• Rutgeerts P et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402–413
  Article CAS Google Scholar
• Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876–885
  Article CAS Google Scholar
• Kinney T et al. (2003) Immunomodulators and “on demand” therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98: 608–612
  CAS PubMed Google Scholar
• Colombel JF et al. (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126: 19–31
  Article CAS Google Scholar
• Ljung et al. (2004) Infliximab in inflammatory bowel disease: clinical outcome in a population-based cohort from Stockholm County. Gut 53: 849–853
  Article CAS Google Scholar
• Sandborn WJ and Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53: 780–782
  Article CAS Google Scholar
• Biancone L et al. (2006) Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55: 228–233
  Article CAS Google Scholar
• Orlando A et al. (2005) Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37: 577–583
  Article CAS Google Scholar
• Persson PG et al. (1994) Crohn's disease and cancer: a population-based cohort study. Gastroenterology 107: 1675–1679
  Article CAS Google Scholar
• Bickston SJ et al. (1999) The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117: 1433–1437
  Article CAS Google Scholar
• Alcain G et al. (2003) Acute leukemia after infliximab therapy. Am J Gastroenterol 98: 2577
  Article Google Scholar
• Losco A et al. (2004) Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 10: 425–429
  Article Google Scholar
• Bucher C et al. (2005) Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 54: 732–733
  Article CAS Google Scholar
• Nicholson T et al. (2005) Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases. Dis Colon Rectum 48: 1651–1655
  Article Google Scholar
• Al-Za'abi AM et al. (2005) Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol 58: 214–216
  Article CAS Google Scholar
• Zagoni T et al. (2005) Carcinoma arising in enterocutan fistulae of Crohn's disease patients: description of two cases. Int J Colorectal Dis 21: 461–464
  Article Google Scholar
• Peyrin-Biroulet L et al. (2006) Colon cancer after infliximab therapy for Crohn's disease in a young patient transplanted for primary sclerosing cholangitis. Gut 101: 2664–2665
  Google Scholar
• Podolsky DK et al. (2006) A 71-year old woman with Crohns' disease and altered mental status. N Engl J Med 354: 1178–1184
  Article CAS Google Scholar
• Lewis JD et al. (2001). Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121: 1080–1087
  Article CAS Google Scholar
• Loftus VE and Sandborn W (2001) Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 121: 1239–1242
  Article Google Scholar
• Brown SL et al. (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46: 3151–3158
  Article CAS Google Scholar
• Parsi MA and Lashner BA (2004) Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Inflamm Bowel Dis 10: 486–487
  Article Google Scholar
• Rutgeerts P et al. (2006) Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther 23: 451–463
  Article CAS Google Scholar
• Chang JT and Lichtenstein GR (2006) Drug insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 3: 220–228
  Article CAS Google Scholar
• Periodic Safety Update Report (PSUR 11) (2005) Infliximab
• Lichtenstein GR et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol 4: 621–630
  Article CAS Google Scholar
• Siegel CA et al. (2006) Risk and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4: 1017–1024
  Article CAS Google Scholar
• Centocor [http://www.centocor.com/index.jsp]
• Chey WY et al. (2001) Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 7 (Suppl): S30–S33
  Article Google Scholar
• Sands BE et al. (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7: 83–88
  Article CAS Google Scholar
• Kaser A et al. (2001) Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 113: 930–933
  CAS PubMed Google Scholar
• Kohn A et al. (2002) Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 34: 626–630
  Article CAS Google Scholar
• Actis GC et al. (2002) Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 34: 631–634
  Article CAS Google Scholar
• Probert CSJ et al. (2003) Infliximab in moderately severe glucorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998–1002
  Article CAS Google Scholar
• Ochsenkuhn T et al. (2004) Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 16: 1167–1171
  Article Google Scholar
• Järnerot G et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805–1811
  Article Google Scholar
• Rutgeerts P et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476
  Article CAS Google Scholar
• Su C et al. (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97: 2577–2584
  Article CAS Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) program. SEER Incidence Crude Rates, 11 Registries, 1993–2001 [http://seer.cancer.gov/] (accessed 28 November 2006)
• Szlosarek PW et al. (2006) Expression and regulation of tumour necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5: 382–390
  Article CAS Google Scholar
• Germanidis G et al. (2005) Regression of inflammatory myofibroblastic tumour of the gastrointestinal tract under infliximab treatment. Dig Dis Sci 50: 262–265
  Article Google Scholar
• Jatoi A et al. (2004) A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 12: 859–863
  Article Google Scholar
• Couriel D et al. (2004) Tumor necrosis factor-alpha blockade for the treatment for the treatment of acute GVHD. Blood 104: 649–654
  Article CAS Google Scholar
• Stack WA et al. (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349: 521–524
  Article CAS Google Scholar
• Sandborn WJ et al. (2001) An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330–1338
  Article CAS Google Scholar
• Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 53: 1485–1493
  Article CAS Google Scholar
• Feagan BG et al. (2005) A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 21: 373–384
  Article CAS Google Scholar
• Feagan BG et al. (2006) CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23: 617–628
  Article CAS Google Scholar
• D'Haens G et al. (2001) Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot study. Am J Gastroenterol 96: 2564–2568
  Article CAS Google Scholar
• Sandborn WJ et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind placebo-controlled trial. Gastroenterology 121: 1089–1094
  Article Google Scholar
• Rutgeerts P et al. (2003) Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17: 185–192
  Article CAS Google Scholar
• Rutgeerts P et al. (2006) Onercept for moderate-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 888–893
  Article CAS Google Scholar
• Sandborn WJ et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984–1989
  Article CAS Google Scholar
• Youdim A et al. (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10: 333–338
  Article Google Scholar
• Papadakis KA et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75–79
  Article CAS Google Scholar
• Hanauer S et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333
  Article CAS Google Scholar
• Winter TA et al. (2004) Intravenous CDP870, a PEGylated Fab' fragment of a humanized anti-tumor necrosis factor antibody, in patients with moderate-to severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 20: 1337–1346
  Article CAS Google Scholar
• Schreiber S et al. (2005) A randomized, placebo-controlled trial of certulizumab pegol (CDP870) for treatment of Crohns' disease. Gastroenterology 129: 807–818
  Article CAS Google Scholar
• Shen C et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251–258
  Article CAS Google Scholar
• Scheinfeld N et al. (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 15: 280–294
  Article CAS Google Scholar
• Hanauer S (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord 4 (Suppl): S18–S24
  PubMed Google Scholar
• Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285
  Article CAS Google Scholar
• Gordon FH et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121: 268–274
  Article CAS Google Scholar
• Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24–32
  Article CAS Google Scholar
• Sandborn WJ et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912–1925
  Article CAS Google Scholar